Sort
82,697 grants matching “vaccine development”
Immunotherapeutics for Treatment of Flavivirus Infection
$1,279,237Erol Fikrig · Yale University · U01 · FY2007 · AI
Sources, Transport, Exposure & Effects of PFAS (STEEP) Center - RENEWAL
$1,279,183Rainer Lohmann · University Of Rhode Island · P42 · FY2025 · ES
Inhibition of hepatitis C by RNA-based therapeutics
$1,279,170Brian H. Johnston · Somagenics, Inc. · R44 · FY2006 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
$1,279,157B. Kim Lee Sim · Sanaria, Inc. · U01 · FY2022 · AI
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
$1,278,909Cheryl L Willman · University Of New Mexico Health Scis Ctr · U2C · FY2023 · CA
CONTROLLED RELEASE POLYMERS FOR BRAIN TUMORS (U19 CA 528
$1,278,774Johns Hopkins University · U19 · FY2003 · CA
Virus-Like Particle Vaccines for Pandemic Influenza
$1,278,207Ted M Ross · University Of Pittsburgh At Pittsburgh · U01 · FY2009 · AI
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
$1,278,096William W. Kwok · Benaroya Research Inst At Virginia Mason · U19 · FY2019 · AI
Immunology, virology, and epidemiology of flaviviruses and other emerging viruses
$1,277,818Leah Katzelnick · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA
$1,277,543Paula Gonzalez · Fundacion Inciensa · N01 · FY2016 · CA
Clinical Trial of Oseltamivir Efficacy for Reducing Influenza Severity
$1,277,517Edward Belongia · Marshfield Clinic Research Foundation · U01 · FY2007 · IP
ADOLESCENT TRIAL NETWORK FOR HIV/AIDS BALTIMORE
$1,277,359University Of Maryland Baltimore · U01 · FY2005 · HD
Cellular and Molecular Physiology of Bloodstream Malaria Parasites
$1,277,294Sanjay A Desai · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
$1,277,195Ruth Margrit Ruprecht · University Of Louisiana At Lafayette · U19 · FY2023 · AI
Role of inflammation, innate resistance, and immunity in carcinogenesis
$1,277,147Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,276,907Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection
$1,276,503Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2023 · AI
International Studies Of Acquired Immune Deficiency Syndrome (AIDS)
$1,275,623Thomas Quinn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
An early life multivalent immunization strategy for induction of neutralization breadth
$1,275,484Ashley Nicole Nelson · Weill Medical Coll Of Cornell Univ · U01 · FY2025 · AI
CTL and HIV Polymorphisms in Heterosexual Transmission
$1,275,465Eric Hunter · Emory University · R01 · FY2009 · AI
Development of multi-modal single-cell technology to dissect epitope specificity to HIV
$1,275,335Steven Edward Bosinger · Emory University · U24 · FY2023 · AI
Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease
$1,274,999Lisa Morici · Tulane University Of Louisiana · N01 · FY2022 · AI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness
$1,274,998Jane C Burns · University Of California, San Diego · R33 · FY2023 · HD
HPV Outcomes: Prevention Epidemiology and Surveillance (HOPES)
$1,274,931Cosette Marie Wheeler · University Of New Mexico Health Scis Ctr · R01 · FY2009 · CA
Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR)
$1,274,599William D Hopkins · University Of Tx Md Anderson Can Ctr · P40 · FY2025 · OD